Email Alert | RSS

北京大学学报（医学版） ›› 2021, Vol. 53 ›› Issue (5): 938-941. doi: 10.19723/j.issn.1671-167X.2021.05.021

• 论著 • 上一篇    下一篇

血清25-羟维生素D与系统性红斑狼疮活动的关系

邹健梅,武丽君(),罗采南,石亚妹,吴雪   

  1. 新疆维吾尔自治区人民医院风湿免疫科,乌鲁木齐 830001
  • 收稿日期:2019-10-23 出版日期:2021-10-18 发布日期:2021-10-11
  • 通讯作者: 武丽君 E-mail:wwlj330@126.com

Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus

ZOU Jian-mei,WU Li-jun(),LUO Cai-nan,SHI Ya-mei,WU Xue   

  1. Department of Rheumatology and Immunology, Xinjiang Uygur Autonomous Region People’s Hospital, Urumqi 830001, China
  • Received:2019-10-23 Online:2021-10-18 Published:2021-10-11
  • Contact: Li-jun WU E-mail:wwlj330@126.com

RICH HTML

 12   

PDF (PC)

134

摘要：

目的: 探讨血清25-羟维生素D[25-dihydroxy vitamin D,25(OH)D]在系统性红斑狼疮(systemic lupus erythematosus,SLE)活动中的应用价值。方法: 收集2016年7月至2019年7月就诊新疆维吾尔自治区人民医院风湿免疫科158例SLE患者。根据SLE疾病活动指数评分(systemic lupus erythematosus disease activity index,SLEADI)将158例SLE患者分为两组:活动组59例(SLEADI>4),非活动组99例(SLEDAI≤4)。选取新疆维吾尔自治区人民医院风湿免疫科体检中心性别、年龄相匹配的健康人群50例作为健康对照组。收集入选患者的一般资料、实验室数据及血清25(OH)D水平。结果: (1)SLE组25(OH)D水平[10.4(5.6,15.8)μg/L]明显低于健康对照组[25.5(22.8,32.3) μg/L,P <0.01];SLE活动组25(OH)D水平为[6.2(3.7,13.8)μg/L],非活动组为[12.3(7.2,16.7) μg/L],组间差异有统计学意义(P<0.01);狼疮肾炎(lupus nephritis,LN)组患者血清25(OH)D水平[6.7(4.4,12.9) μg/L]明显低于SLE无肾脏损害患者[13.3(7.4,18.7) μg/L,P <0.01]。(2)SLE患者中25(OH)D水平与SLEDAI、24h尿蛋白定量(24h urinary protein quantification,24h-pro)升高均呈负相关(r=-0.35和-0.39,P<0.01);与补体C3降低呈正相关(r=0.24,P<0.01)。(3)通过单因素分析发现抗双链DNA抗体(anti-ds DNA antibodies,ds-DNA)、抗史密斯抗体(anti-Smith antibodies,Sm)、IgG、C3、C4、红细胞沉降率(erythrocyte sedimentation rate,ESR)、24h-pro以及25(OH)D与SLE患者疾病活动相关,通过多因素Logistic回归分析发现25(OH)D降低是SLE患者疾病活动的独立危险因素。结论: 血清25(OH)D的下降与SLE患者病情活动有相关性,而且可能与LN相关,在SLE的发生、发展中有重要作用。

关键词: 系统性红斑狼疮, 狼疮肾炎, 25-羟维生素D, 疾病活动

Abstract:

Objective: To investigate the application value of serum 25-hydroxy vitamin D [25(OH)D] in systemic lupus erythematosus (SLE). Methods: Data of 158 patients with SLE in Department of Rheumatology and Immunology in the People’s Hospital of Xinjiang Uygur Autonomous Region from July 2016 to July 2019. All the SLE patients were divided into two groups by SLE scores of the disease activity index (SLEADI): 59 cases of active group (SLEADI>4), 99 cases of non-active group (SLEDAI ≤4). Fifty healthy people were selected as healthy control group. The patients’ general information and their laboratory data including serum 25(OH)D levels were collected. Statistical methods used were t-test, Spearman’s correalation analysis and Logistic regression analysis. Results: (1) A total of 208 cases were included in this study. The level of 25(OH)D in SLE group [10.4(5.6,15.8) μg/L] was significantly lower than that in healthy control group [25.5(22.8,32.3) μg/L, P<0.01]. 25(OH)D level in active SLE patients [6.2(3.7,13.8) μg/L] was significantly lower than that in remission SLE patients [12.3(7.2,16.7) μg/L, P<0.01]. The serum 25(OH)D level in lupus nephritis [6.7 (4.4, 12.9) μg/L] was significantly lower than that in SLE without renal involvement [13.3 (7.4, 18.7) μg/L, P<0.01]. (2) A significant negative correlation was demonstrated between the serum level of 25(OH)D and SLEDAI (r=-0.35,P<0.01), and the 24h urinary protein excretion (r=-0.39, P<0.01).Positive correlation was demonstrated between the serum level of 25(OH)D and C3 that decreased (r=0.249, P<0.05). (3) Univariate analysis showed anti- dsDNA antibodies(ds-DNA), anti-Sm antibodies(Sm), IgG, C3, C4, erythrocyte sedimentation rate (ESR), 24h urinary protein quantification(24h-pro) and 25(OH)D were associated with disease activity in the SLE patients; Multivariate Logistic regression analysis showed that 25(OH)D was associated with the disease activity of the lupus patients. Conclusion: The decrease of vitamin D level is related to the disease activity of SLE patients, and may be related to lupus nephritis, which plays an important role in the occurrence and development of SLE.

Key words: Systemic lupus erythematosus, Lupus nephritis, 25-hydroxy vitamin D, Disease activity

中图分类号: 

  • R593.24

表1

SLE患者活动组与非活动组一般数据对比"

Items Active group Non-active group P
Cases, n(%) 59 (37) 99 (63) 0.95
Gender, n(%)
Female 55 (34.8) 92 (58.3)
Male 4 (2.5) 7 (4.4)
Age/year, x ?±s 25.1±12.9 24.8±12.7 0.88
Course of disease/month, M (P25, P75) 9.6 (4.8, 12.0) 13.2 (10.8, 36.0) <0.01
ANA, n(%), M (P25, P75) 59 (100) 97 (98.0) 0.82
ds-DNA, n(%), M (P25, P75) 30 (50.8) 12 (12.1) <0.01
Sm, n(%), M (P25, P75) 19 (32.2) 12 (12.2) <0.05
SSA, n(%), M (P25, P75) 30 (50.8) 53 (54.1) 0.70
SSB, n(%), M (P25, P75) 7 (11.9) 10 (10.2) 0.75
Acl/(RU/mL), M (P25, P75) 3.4 (2.0, 8.3) 2.3 (2.0, 4.8) 0.06
β2-GPI/(RU/mL), M (P25, P75) 5.1 (2.0, 12.9) 5.9 (2.2, 13.3) 0.67
C1q/(AU/mL), M (P25, P75) 49.0 (8.3, 174.0) 7.7 (3.9, 26.9) <0.01
Complement C1q/(mg/L), M (P25, P75) 169.0 (129.8, 210.9) 165.4 (138.0, 26.9) 0.98
IgG/(g/L), M (P25, P75) 13.5 (8.6, 22.1) 12.5 (10.1, 16.4) 0.33
IgA/(g/L), M (P25, P75) 2.6 (1.6, 3.4) 2.3 (1.5, 3.3) 0.61
IgM/(g/L), M (P25, P75) 1.0 (0.6, 1.3) 0.9 (0.6, 0.9) 0.61
C3/(g/L), M (P25, P75)
C4/(g/L), M (P25, P75)
ESR/(mm/H), M (P25, P75)
CRP/(mg/L), M (P25, P75)
24h-pro/(g), M (P25, P75)
BUN/(mmol/L), M (P25, P75)
Cr/(μmol/L), M (P25, P75)
BGP/(μg/L), M (P25, P75)
25(OH)D/(μg/L), M (P25, P75)		 0.6 (0.4, 0.8)
0.1 (0.0, 0.1)
41.0 (20.3, 54.0)
5.0 (2.5, 15.0)
0.3 (0.1, 1.9)
5.6 (3.9, 8.2)
56.7 (48.2, 71.2)
8.0 (5.0, 13.8)
6.2 (3.7, 13.8)		 0.8 (0.9, 0.6)
0.1 (0.1, 0.2)
18.0 (10.8, 28.0)
2.8 (1.9, 5.0)
0.1 (0.0, 0.1)
4.6 (3.6, 5.4)
57.8 (49.8, 64.3)
10.0 (7.0, 14.0)
12.3 (7.2, 16.7)		 <0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.58
0.11
<0.01
[1] Cutolo M, Otsa K. Review: Vitamin D, immunity and lupus [J]. Lupus, 2008, 17(1):6-10.
pmid: 18089676
[2] Kamen DL. Vitamin D in lupus-new kid on the block? [J]. Bull NYU Hosp Jt Dis, 2010, 68(3):218-222.
[3] Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus [J]. Ann Rheum Dis, 2011, 70(9):1569-1574.
doi: 10.1136/ard.2010.148494 pmid: 21586442
[4] Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? [J]. Ann Rheum Dis, 2010, 69(6):1155-1157.
doi: 10.1136/ard.2009.120329 pmid: 20439290
[5] Yeap SS, Othman AZ, Zain AA, et al. Vitamin D levels: Its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids [J]. Int J Rheum Dis, 2012, 15(1):17-24
doi: 10.1111/apl.2012.15.issue-1
[6] Souto M, Coelho A, Guo C, et al. Vitamin D insufficiency in Brazilian patients with SLE: Prevalence, associated factors, and relationship with activity [J]. Lupus, 2011, 20(10):1019-1026.
doi: 10.1177/0961203311401457 pmid: 21646315
[7] De Souza VA, Bastos MG, Fernandes NM, et al. Association of hypovitaminosis D with systemic lupus erythematosus and inflammation [J]. Bras Nefrol, 2014, 36(4):430-436.
[8] Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis [J]. Rheumatology (Oxford), 2008, 47(11):1617-1621.
doi: 10.1093/rheumatology/ken296 pmid: 18682414
[9] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40(9):1725-1734.
[10] Ding Y, Liao W, He XJ, et al. Effects of 1,25(OH)2 D3 and vitamin D receptor on peripheral CD4+/CD8+double-positive T lymphocytes in a mouse model of systemic lupus erythematosus [J]. J Cell Mol Med, 2017, 21(5):975-985.
doi: 10.1111/jcmm.13037 pmid: 28063200
[11] Mok CC. Vitamin D and systemic lupus erythematosus: an update [J]. Expert Rev Clin Immunol, 2013, 9(5):453-463.
doi: 10.1586/eci.13.19
[12] 张竞, 罗静, 王静, 等. 血清25(OH)D水平与初诊系统性红斑狼疮疾病活动度的相关性研究 [J]. 中华风湿病学杂志, 2019, 23(1):36-41.
[13] 方慧玲, 禹松林, 韩建华, 等. 中国北方健康人群血清 25羟维生素D3和25羟维生素D2水平 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2014, 7(3):199-205.
[14] Cashman KD, Dowling KG. Vitamin D deficiency in Europe: Pandemic? [J]. Am J Clin Nutr, 2016, 103(4):1033-1044.
doi: 10.3945/ajcn.115.120873 pmid: 26864360
[15] 张永锋, 郑毅. 初发系统性红斑狼疮患者血清25-羟-维生素D和维生素D抗体水平变化及意义 [J]. 中华风湿病学杂志, 2012, 16(10):661-664.
[16] 卢勤燕, 蔡小燕, 林小军, 等. 系统性红斑狼疮患者外周血维生素D水平及其临床意义 [J]. 实用医学杂志, 2015, 31(7):1123-1125.
[17] 洪琼. 25羟基维生素D与类风湿关节炎及系统性红斑狼疮的相关性研究 [D]. 安徽, 安徽医科大学, 2013: 1-108.
[18] Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synjournal on the incidence of autoimmune disease [J]. Nat Clin Pract Rheumatol, 2009, 5(2):99-105.
doi: 10.1038/ncprheum0989 pmid: 19182816
[19] 陈铭聿, 孙彬, 张波, 等. 狼疮肾炎患者血维生素D3水平与疾病活动度的相关性研究 [J]. 中华肾脏病杂志, 2015, 31(2):881-886.
[1] 田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087.
[2] 夏芳芳,鲁芙爱,吕慧敏,杨国安,刘媛. 系统性红斑狼疮伴间质性肺炎的临床特点及相关因素分析[J]. 北京大学学报（医学版）, 2021, 53(2): 266-272.
[3] 耿研,李伯睿,张卓莉. 系统性红斑狼疮患者有症状关节病变的肌肉骨骼超声特点[J]. 北京大学学报（医学版）, 2020, 52(1): 163-168.
[4] 王玉华,张国华,张令令,罗俊丽,高兰. 系统性红斑狼疮合并自发性肾上腺出血1例[J]. 北京大学学报（医学版）, 2019, 51(6): 1178-1181.
[5] 李英妮,相晓红,赵静,李云,孙峰,王红彦,贾汝琳,胡凡磊. 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报（医学版）, 2019, 51(6): 1019-1024.
[6] 肖榆冰,郭慕瑶,左晓霞. 免疫代谢与系统性红斑狼疮[J]. 北京大学学报（医学版）, 2018, 50(6): 1120-1124.
[7] 杨帆,周云杉,贾园. 系统性红斑狼疮合并获得性血友病A 1例[J]. 北京大学学报（医学版）, 2018, 50(6): 1108-1111.
[8] 李胜光,张清,周惠琼. 抗中性粒细胞胞质抗体相关性血管炎的病情评估方法及其相关性[J]. 北京大学学报（医学版）, 2018, 50(6): 1022-1026.
[9] 刘爽,郭雨龙,杨静逸,王维,徐健. 间充质干细胞治疗系统性红斑狼疮有效性的meta分析[J]. 北京大学学报（医学版）, 2018, 50(6): 1014-1021.
[10] 陈晓梅，李静，张晓盈，金月波，余迪，孙晓麟，武丽君，何菁，栗占国. 不同亚型的滤泡辅助性T淋巴细胞在类风湿关节炎中的临床意义[J]. 北京大学学报(医学版), 2016, 48(6): 958-963.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报（医学版）, 2009, 41(2): 135 -140 .
[4] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[5] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[6] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报（医学版）, 2009, 41(1): 109 -111 .
[7] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[8] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报（医学版）, 2009, 41(5): 599 -601 .
[9] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
[10] 丰雷, 王玉凤, 曹庆久. 哌甲酯对注意缺陷多动障碍儿童平衡功能影响的开放性研究[J]. 北京大学学报（医学版）, 2007, 39(3): 304 -309 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部